Literature DB >> 10479741

Depression in patients with Parkinson's disease.

J L Cummings1, D L Masterman.   

Abstract

Parkinson's disease (PD) is a disabling neurodegenerative condition commonly complicated by the existence of comorbid depression. The prevalence rates of depression in this patient group have been reported to be as high as 40%. Currently, depression in PD is undertreated; there have been few controlled clinical trials of antidepressants in this patient group. Patients with PD are usually elderly and often administered a range of medication, therefore the choice of antidepressant must be undertaken with care. Tricyclic antidepressants (TCAs) have been studied in patients with PD and comorbid depression; however, the risk of anticholinergic side-effects means that their use is largely avoided. Selective serotonin reuptake inhibitors have comparable efficacy to the TCAs and a better tolerability profile in patients with depression; they are rapidly being considered as first-line therapy for PD patients with depression. Clinical studies in this patient group are warranted. This article reviews the characteristics of comorbid depression in patients with PD and discusses the treatment options available. Copyright 1999 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10479741

Source DB:  PubMed          Journal:  Int J Geriatr Psychiatry        ISSN: 0885-6230            Impact factor:   3.485


  30 in total

1.  Depression in Parkinson's disease.

Authors:  H Allain; S Schuck; N Mauduit
Journal:  BMJ       Date:  2000-05-13

Review 2.  Neuropsychiatry of the basal ganglia.

Authors:  H A Ring; J Serra-Mestres
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-01       Impact factor: 10.154

3.  Exendin-4 reverts behavioural and neurochemical dysfunction in a pre-motor rodent model of Parkinson's disease with noradrenergic deficit.

Authors:  N Rampersaud; A Harkavyi; G Giordano; R Lever; J Whitton; Ps Whitton
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

4.  Gender and the Parkinson's disease phenotype.

Authors:  Yasuhiko Baba; John D Putzke; Nathaniel R Whaley; Zbigniew K Wszolek; Ryan J Uitti
Journal:  J Neurol       Date:  2005-09-12       Impact factor: 4.849

Review 5.  Intranasal administration of neurotoxicants in animals: support for the olfactory vector hypothesis of Parkinson's disease.

Authors:  Rui D S Prediger; Aderbal S Aguiar; Filipe C Matheus; Roger Walz; Layal Antoury; Rita Raisman-Vozari; Richard L Doty
Journal:  Neurotox Res       Date:  2011-10-15       Impact factor: 3.911

6.  Assessing depression and factors possibly associated with depression during the course of Parkinson's disease.

Authors:  Amy H Farabaugh; Joseph J Locascio; Liang Yap; Maurizio Fava; Stella Bitran; Jessica L Sousa; John H Growdon
Journal:  Ann Clin Psychiatry       Date:  2011-08       Impact factor: 1.567

7.  Effects of Antidepressants on DSP4/CPT-Induced DNA Damage Response in Neuroblastoma SH-SY5Y Cells.

Authors:  Yan Wang; Benjamin A Hilton; Kui Cui; Meng-Yang Zhu
Journal:  Neurotox Res       Date:  2015-06-03       Impact factor: 3.911

8.  Cost of illness and its predictors for Parkinson's disease in Germany.

Authors:  Annika E Spottke; Martin Reuter; Olaf Machat; Bernhard Bornschein; Sonja von Campenhausen; Karin Berger; Rudolf Koehne-Volland; Jürgen Rieke; Alexander Simonow; Dirk Brandstaedter; Uwe Siebert; Wolfgang H Oertel; Gudrun Ulm; Richard Dodel
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 9.  The significance of subsyndromal depression in geriatrics.

Authors:  Helen Lavretsky; Kristina Kurbanyan; Anand Kumar
Journal:  Curr Psychiatry Rep       Date:  2004-02       Impact factor: 5.285

10.  Telephone-administered cognitive behavioral therapy: a case study of anxiety and depression in Parkinson's disease.

Authors:  Connie Veazey; Karon F Cook; Melinda Stanley; Eugene C Lai; Mark E Kunik
Journal:  J Clin Psychol Med Settings       Date:  2009-04-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.